Prevention of Recurrence of Diverticulitis

NCT ID: NCT00545740

Last Updated: 2021-06-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

590 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-28

Study Completion Date

2012-03-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether SPD476 is effective in reducing recurrence of diverticulitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diverticulitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SPD476 (1.2 g)

Group Type EXPERIMENTAL

SPD476 (1.2g)

Intervention Type DRUG

1.2g SPD476 once daily (QD) orally

SPD476 (2.4 g)

Group Type EXPERIMENTAL

SPD476 (2.4 g)

Intervention Type DRUG

2.4g SPD476 QD orally

SPD476 (4.8 g)

Group Type EXPERIMENTAL

SPD476 (4.8 g)

Intervention Type DRUG

4.8g SPD476 QD orally

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

QD orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SPD476 (1.2g)

1.2g SPD476 once daily (QD) orally

Intervention Type DRUG

SPD476 (2.4 g)

2.4g SPD476 QD orally

Intervention Type DRUG

SPD476 (4.8 g)

4.8g SPD476 QD orally

Intervention Type DRUG

Placebo

QD orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lialda, MMX™ mesalazine Lialda, MMX™ mesalazine Lialda, MMX™ mesalazine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females =\>18yrs of age.
2. If female of childbearing potential (FOCP), has demonstrated a negative beta HCG (human chorionic gonadotropin) serum pregnancy test, and agrees to comply with any applicable contraceptive requirements of the protocol.
3. An episode of acute diverticulitis that resolved without colonic resection.
4. Confirmation of diverticulosis via endoscopic evaluation of the sigmoid colon with at least three diverticula noted.

Exclusion Criteria

1. Previous colorectal surgery, including surgical intervention for diverticular disease (with the exception of haemorrhoidectomy, colonic removal of polyps, and appendectomy)
2. Active peptic ulcer disease
3. History of or current presence of inflammatory bowel disease (IBD)
4. Subjects with active irritable bowel syndrome (IBS) requiring ongoing medication
5. Allergy or hypersensitivity to aspirin or related compounds
6. Allergy to radiologic contrast agents
7. Use of another Investigational product within 30 days of Baseline
8. Use of antibiotic therapy within 4 weeks of Baseline
9. Within 14 days of Baseline, use of prebiotic, probiotic or 5-ASA medications, as well as drugs active at the 5HT-receptor or anti-spasmodic agents
10. Use of systemic or rectal steroids within 6 weeks of Baseline. Use of inhaled or nasal steroids is acceptable
11. Use of anti-inflammatory drugs, (NSIADs, COX-2 inhibitors) including aspirin (except for cardiac prophylaxis) and ibuprofen, on a regular and ongoing basis
12. History of alcohol or other substance abuse within the previous year
13. Active or recent history of endometriosis or dysmenorrhoea within 6 months prior to Baseline
14. Females who are lactating
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shire

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dedicated Clinical Research

Litchfield Park, Arizona, United States

Site Status

Lynn Institute of the Ozarks

Little Rock, Arkansas, United States

Site Status

Advanced Clinical Research Institute

Anaheim, California, United States

Site Status

GW Research

Chula Vista, California, United States

Site Status

Monterey Bay GI Research Institute, Inc

Monterey, California, United States

Site Status

Rancho Cucamonga C. Trials

Rancho Cucamonga, California, United States

Site Status

Clinical Trials Research

Roseville, California, United States

Site Status

Medical Associates Research

San Diego, California, United States

Site Status

Torrance Clinical Research

Torrance, California, United States

Site Status

Rocky Mountain Gastroenterology Associates

Thornton, Colorado, United States

Site Status

Gastroenterology Associates of Fairfield County

Bridgeport, Connecticut, United States

Site Status

Yale Center for Clinical Investigation

New Haven, Connecticut, United States

Site Status

ZASA Clinical Research

Boynton Beach, Florida, United States

Site Status

Clinical Research of West Florida, Inc.

Clearwater, Florida, United States

Site Status

Borland-Groover Clinic

Jacksonville, Florida, United States

Site Status

Compass Research

Orlando, Florida, United States

Site Status

Accord Clinic Research, LLC

Port Orange, Florida, United States

Site Status

Florida Medical Clinic/Tampa Clinical Trials

Tampa, Florida, United States

Site Status

Gastroenterology Associates of Central Georgia, LLC

Macon, Georgia, United States

Site Status

Saint John's Research Institute

Anderson, Indiana, United States

Site Status

Digestive & Liver Disease Consultants

Clive, Iowa, United States

Site Status

New Orleans Research Institute

Metairie, Louisiana, United States

Site Status

Digestive Disease Associates

Baltimore, Maryland, United States

Site Status

Endoscopic Microsurgery Associates, PA

Towson, Maryland, United States

Site Status

Borgess Research Institute

Kalamazoo, Michigan, United States

Site Status

Jefferson City Medical Group

Jefferson City, Missouri, United States

Site Status

South Jersey Gastroenterology, P.A.

Marlton, New Jersey, United States

Site Status

Howard Guss, DO

Ocean City, New Jersey, United States

Site Status

New Jersey Physicians, LLC

Passaic, New Jersey, United States

Site Status

Allied Gastrointestinal Associates, P.A.

Voorhees Township, New Jersey, United States

Site Status

Regional Clinical Research

Endwell, New York, United States

Site Status

Long Island Clinical Research Associates

Great Neck, New York, United States

Site Status

Long Island Gastrointestinal Research Group

Great Neck, New York, United States

Site Status

Research Associates of New York

New York, New York, United States

Site Status

Vital Research

Greensboro, North Carolina, United States

Site Status

Gastroenterology Specialists, Inc

Canton, Ohio, United States

Site Status

Memorial Research Center

Chattanooga, Tennessee, United States

Site Status

Gastroenterology Associates Clinical Research

Kingsport, Tennessee, United States

Site Status

Nashville Medical Research Institute

Nashville, Tennessee, United States

Site Status

Harris Methodist Fort Worth Hospital

Fort Worth, Texas, United States

Site Status

Kelsey-Seybold Clinic

Houston, Texas, United States

Site Status

Clinical Trials of Texas, Inc.

San Antonio, Texas, United States

Site Status

Stone Oak Research Foundation

San Antonio, Texas, United States

Site Status

Blue Ridge Medical Research

Lynchburg, Virginia, United States

Site Status

Digestive and Liver Disease Specialists

Norfolk, Virginia, United States

Site Status

Aurora Advanced Healthcare, Inc. - Clinical Research Center

Milwaukee, Wisconsin, United States

Site Status

CIMEL

Lanús, Buenos Aires, Argentina

Site Status

Instituto Gamma

Rosario, Santa Fe Province, Argentina

Site Status

Hospital Bocalandro

Buenos Aires, , Argentina

Site Status

Hospital Heroes de Malvinas

Buenos Aires, , Argentina

Site Status

GEDYT

Buenos Aires, , Argentina

Site Status

Sanatorio Guemes

Buenos Aires, , Argentina

Site Status

Cibic S.A.

Santa Fe, , Argentina

Site Status

The Canberra Hospital

Garran, Australian Capital Territory, Australia

Site Status

Ballarat Base Hospital

Ballarat, Victoria, Australia

Site Status

St Vincent's Hospital (Melb) LTD

Melbourne, Victoria, Australia

Site Status

Royal Adelaide Hospital

Adelaide, , Australia

Site Status

Royal Prince Albert Hospital

Camperdown, , Australia

Site Status

Frankston Private

Frankston, , Australia

Site Status

Bayside Gastroenterology

Frankston, , Australia

Site Status

Fremantle Hospital

Fremantle, , Australia

Site Status

Ugasend S.A

Barranquilla, , Colombia

Site Status

Clinica Colsinatas SA

Bogotá, , Colombia

Site Status

FOQUS, Centro de Investigacion Clinica

Bogotá, , Colombia

Site Status

Fundacion Clinica Abood Shaio

Bogotá, , Colombia

Site Status

Hospital Universitario San Ignacio

Bogotá, , Colombia

Site Status

Clinica Las Americas

Medellín, , Colombia

Site Status

CHU de Strasbourg

Strasbourg, Alsace, France

Site Status

CHU de Grenoble

Grenoble, Auvergne-Rhône-Alpes, France

Site Status

Hepato Gastro Enterology

Nantes, Brittany Region, France

Site Status

Hopital Charles Nicolle

Rouen, Normandy, France

Site Status

Hopital Beaujon

Clichy, Paris, France

Site Status

Cabinet de Gastro-enterologie du Dr Alain Thevenin

Saint-Quentin, Picardie, France

Site Status

Clinique Bouchard

Marseille, Provence-Alpes-Côte d'Azur Region, France

Site Status

Hopital I'Archet

Nice, Provence-Alpes-Côte d'Azur Region, France

Site Status

Cabinet du Dr Olivier Delette

Lille, , France

Site Status

Dr Michel Regensberg

Paris, , France

Site Status

Baby Memorial Hospital

Calicut, Kerala, India

Site Status

Lakeshore Hospital & Research Centre Ltd

Kochi, Kerala, India

Site Status

Sree Gokulam Medical College and Research Foundation

Trivandrum, Kerala, India

Site Status

Dayanand Medical College and Hospital

Ludhiana, Punjab, India

Site Status

S R Kalla Memorial Hospital

Jaipur, Rajasthan, India

Site Status

Aceer

Chennai, Tamil Nadu, India

Site Status

Institute of Postgraduate Medical Education and Research

Kolkata, West Bengal, India

Site Status

Brahmin Mitra Mandal Society

Ahmedabad, , India

Site Status

Ruby Hall Clinic

Pune, , India

Site Status

Krishna Institute of Medical Sciences

Secunderabad, , India

Site Status

Emek Medical Center

Afula, , Israel

Site Status

Barzilai Medical Centre

Ashkelon, , Israel

Site Status

Soroka Medical Center

Beersheba, , Israel

Site Status

Bnai Zion Medical Center

Haifa, , Israel

Site Status

Rambam Medical Center

Haifa, , Israel

Site Status

Hadassah Ein-Karem Medical Center

Jerusalem, , Israel

Site Status

Meir Medical Centre

Kfar Saba, , Israel

Site Status

Rabin Medical Center

Petah Tikva, , Israel

Site Status

Kaplan Medical Center

Rehovot, , Israel

Site Status

The Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

The Chaim Sheba Medical Center

Tel Litwinsky, , Israel

Site Status

Assaf Harofeh Medical Center

Ẕerifin, , Israel

Site Status

Shakespeare Specialist Group

Takapuna, Auckland, New Zealand

Site Status

Auckland City Hospital

Auckland, , New Zealand

Site Status

CURT Medical Trials Trust Board

Christchurch, , New Zealand

Site Status

Dunedin Hospital

Dunedin, , New Zealand

Site Status

Waikato Hospital

Hamilton, , New Zealand

Site Status

Tauranga Hospital

Tauranga, , New Zealand

Site Status

Hospital Valle de Hebron

Barcelona, , Spain

Site Status

Hospital Universitario de Bellvitge

Barcelona, , Spain

Site Status

Hospital de Donostia

Donostia / San Sebastian, , Spain

Site Status

Hospital Son Dureta

Palma de Mallorca, , Spain

Site Status

Hospital General Universitario de Valencia

Valencia, , Spain

Site Status

University Hospital/Eastern Hospital

Gothenburg, , Sweden

Site Status

University Hospital Linköping

Linköping, , Sweden

Site Status

VO Internmedicin

Stockholm, , Sweden

Site Status

Karolinska University Hospital

Stockholm, , Sweden

Site Status

Danderyd Hospital

Stockholm, , Sweden

Site Status

Kirurgkliniken

Uppsala, , Sweden

Site Status

Norfolk/Norwich University Hospital

Norwich, East Anglia, United Kingdom

Site Status

St Mark's Hospital

Harrow, London, United Kingdom

Site Status

King's College Hospital

London, , United Kingdom

Site Status

Chelsea & Westminster Hospital

London, , United Kingdom

Site Status

Imperial College London

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Colombia France India Israel New Zealand Spain Sweden United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Raskin JB, Kamm MA, Jamal MM, Marquez J, Melzer E, Schoen RE, Szaloki T, Barrett K, Streck P. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology. 2014 Oct;147(4):793-802. doi: 10.1053/j.gastro.2014.07.004. Epub 2014 Jul 16.

Reference Type DERIVED
PMID: 25038431 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2007-004895-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

SPD476-313

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.